Create Free Account

By creating account you will get access to hot stocks & personalised emails

Botanix Pharmaceuticals Ltd

Healthcare AU BOT

0.39AUD
0.005(1.30%)

Last update at 2024-12-19T05:11:00Z

Day Range

0.380.41
LowHigh

52 Week Range

0.160.45
LowHigh

Fundamentals

  • Previous Close 0.39
  • Market Cap717.96M
  • Volume8671019
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-13.91937M
  • Revenue TTM2.07M
  • Revenue Per Share TTM0.001
  • Gross Profit TTM -1.95513M
  • Diluted EPS TTM-0.01

Analyst Recommendations

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Income before tax -9.15397M -13.17075M -3.33400M -16.73071M -17.03921M
Minority interest - - - - -
Net income -9.15397M -13.17075M -10.27537M -24.18044M -17.05042M
Selling general administrative 3.04M 3.56M 2.24M 8.25M 3.19M
Selling and marketing expenses - - - - -
Gross profit -5.62456M 0.10M - - -11.94435M
Reconciled depreciation 0.11M 0.14M 0.09M 0.10M 0.00158M
Ebit -9.07224M -13.13331M -3.27806M -16.67973M -17.02801M
Ebitda -8.96180M -12.98981M -3.18384M -16.57745M -17.02642M
Depreciation and amortization 0.11M 0.14M 0.09M 0.10M 0.00158M
Non operating income net other - - - - -
Operating income -9.12634M -13.13331M -3.27806M -16.67973M -17.02801M
Other operating expenses -1.45557M 15.94M 10.27M 24.26M 21.46M
Interest expense 0.08M 0.04M 0.06M 0.05M 0.01M
Tax provision 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Interest income 0.09M 0.04M 0.06M 0.22M 0.00524M
Net interest income -0.01578M -0.00007M 0.05M -0.05098M 0.11M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 3.74M 2.81M 6.94M 7.45M 0.01M
Total revenue 0.10M 0.10M 0.10M 0.18M 0.19M
Total operating expenses 12.90M 15.94M 10.27M 24.26M 21.46M
Cost of revenue 5.73M - - - 16.63M
Total other income expense net 3.66M 2.77M -0.05594M -0.05098M -0.01121M
Discontinued operations - - - - -
Net income from continuing ops -9.15397M -13.17075M -3.33400M -16.73071M -17.03921M
Net income applicable to common shares -9.15397M -13.17075M -3.33400M -16.73071M -17.03921M
Preferred stock and other adjustments - - - - -
Breakdown 2024-06-30 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Type yearly yearly yearly yearly yearly
Date 2024-06-30 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Total assets 112.46M 24.84M 14.04M 21.95M 25.31M
Intangible assets - 10.73M 3.30M 3.30M -
Earning assets - - - - -
Other current assets 1.57M 0.09M 0.03M 0.00992M 0.00147M
Total liab 3.73M 1.88M 5.89M 1.15M 1.67M
Total stockholder equity 108.73M 22.95M 8.15M 20.80M 23.64M
Deferred long term liab - 3.87M - - -
Other current liab 1.00M 0.49M 1.20M 0.39M 0.37M
Common stock 188.32M 93.49M 71.48M 71.48M 71.41M
Capital stock - 93.49M 71.48M 71.48M 71.41M
Retained earnings -90.79164M -76.92193M -67.76796M -54.59721M -51.26321M
Other liab - - - - -
Good will - - - - -
Other assets 0.00000M 3.94M 0.06M 0.06M 0.09M
Cash 79.31M 10.25M 7.29M 21.55M 24.65M
Cash and equivalents - - - - -
Total current liabilities 3.73M 1.88M 5.89M 1.04M 1.38M
Current deferred revenue - - -1.10828M -0.14714M -0.12433M
Net debt -79.30813M -10.25039M -7.16324M -21.29559M -24.22456M
Short term debt - 0.00000M 0.12M 0.15M 0.12M
Short long term debt - - - - -
Short long term debt total - - 0.12M 0.26M 0.42M
Other stockholder equity - -16.56773M -3.70781M -16.87855M -20.15115M
Property plant equipment - 0.07M 0.18M 0.28M 0.45M
Total current assets 82.90M 13.98M 10.50M 21.61M 24.78M
Long term investments - - 0.06M 0.06M 0.09M
Net tangible assets - 16.10M 4.86M 20.80M 23.64M
Short term investments - - - - -
Net receivables 0.82M 0.49M 0.14M 0.05M 0.13M
Long term debt - - - - -
Inventory 1.21M 3.15M 3.04M 3.04M -
Accounts payable 2.73M 1.39M 5.67M 0.65M 1.01M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 11.20M 6.38M 4.44M 3.92M 3.49M
Additional paid in capital - - - - -
Common stock total equity - - - - 71.41M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 29.49M 0.06M 0.06M 0.06M -
Deferred long term asset charges - - - - -
Non current assets total 29.56M 10.86M 3.54M 0.34M 0.53M
Capital lease obligations - - 0.12M 0.26M 0.42M
Long term debt total - 0.00000M 0.00000M 0.11M 0.30M
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Investments -7.05372M -2.92187M -0.00828M -0.15119M -0.01329M
Change to liabilities -4.03868M 4.65M -0.38174M -3.40955M 3.12M
Total cashflows from investing activities -7.05372M -2.92187M -0.00828M -0.15119M -0.01329M
Net borrowings -0.12241M -0.15241M -0.12550M -0.02308M -0.02308M
Total cash from financing activities 22.03M -0.15241M -0.12550M 37.31M 0.57M
Change to operating activities - - - - -
Net income -9.15397M -13.17075M -3.33400M -16.73071M -17.05042M
Change in cash 2.96M -14.26925M -3.09028M 19.94M -12.55895M
Begin period cash flow 7.29M 21.55M 24.65M 4.70M 17.26M
End period cash flow 10.25M 7.29M 21.55M 24.65M 4.70M
Total cash from operating activities -12.07406M -11.18406M -2.96802M -17.35859M -13.14072M
Issuance of capital stock 23.59M - - 40.49M 0.60M
Depreciation 0.11M 0.14M 0.09M 0.10M 0.00158M
Other cashflows from investing activities - - 0.00000M -0.06114M -0.06114M
Dividends paid -1.84924M 20.30M - - -
Change to inventory -0.10268M -3.04435M -3.04435M -3.04435M -3.04435M
Change to account receivables -0.40999M -0.09680M 0.09M 0.35M -0.05663M
Sale purchase of stock -1.43836M -1.43836M 0.00000M -3.15873M -0.02676M
Other cashflows from financing activities 3.58M -0.15241M -0.12550M -0.02308M -0.01329M
Change to netincome 1.52M 1.84M 0.57M 2.33M 0.84M
Capital expenditures 7.05M 2.92M 0.00828M 0.09M 0.01M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -0.51267M -3.14114M 0.09M 0.35M 4.81M
Stock based compensation 1.52M 0.33M 0.57M 2.33M -
Other non cash items -3.03052M 1.84M 0.27M -0.73016M 17.04M
Free cash flow -19.12778M -14.10592M -2.97630M -17.44864M -13.15401M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
BOT
Botanix Pharmaceuticals Ltd		 0.005 1.30% 0.39 - - 346.93 6.44 1148.36 -11.0772
CSL
CSL Ltd		 -3.45 1.22% 278.79 32.86 33.00 9.11 5.02 6.65 20.64
TLX
Telix Pharmaceuticals Ltd		 -0.07 0.27% 25.67 161.73 75.19 12.58 19.98 12.52 109.28
MSB
Mesoblast Ltd		 1.07 54.04% 3.05 - 454.55 312.43 2.49 67.90 -9.8623
NEU
Neuren Pharmaceuticals Ltd		 -0.36 2.79% 12.54 13.51 35.21 8.91 5.13 6.48 8.45

Reports Covered

Stock Research & News

View All

Profile

Botanix Pharmaceuticals Limited engages in the research and development of dermatology and antimicrobial products in Australia and the United States. Its product pipeline includes Sofpironium Bromide, a drug in development for the treatment of primary axillary hyperhidrosis that has completed Phase 3 clinical programs; BTX 1503, a transdermal gel formulation for the treatment of serious acne in adults and teenagers that has completed Phase II clinical trials; BTX 1801, which has completed Phase IIa clinical trials for the treatment of staphylococcus aureus and methicillin resistant staphylococcus aureus; BTX 1702 that is in Phase II clinical trials for the treatment of papulopustular rosacea; and BTX 1204A for the treatment of atopic dermatitis. Botanix Pharmaceuticals Limited was incorporated in 1984 and is based in West Perth, Australia.

Botanix Pharmaceuticals Ltd

41 ? 47 Colin Street, West Perth, WA, Australia, 6005

Key Executives

Name Title Year Born
Mr. Vincent P. Ippolito MD & Exec. Chairman 1959
Dr. Howie McKibbon Chief Operating Officer NA
Dr. Henry William Bosch BA, Ph.D. Chief Scientific Officer & Exec. Director NA
Mr. Matthew Callahan L.L.B., M.B.A., MBA LLB Exec. Director 1973
Dr. Clarence L. Young M.D. Chief Medical Officer 1956
Ms. Lynda Berne Head of Commercial NA
Dr. Jack Hoblitzell Ph.D. Sr. VP of Pharmaceutical Devel. NA
Dr. Patricia S. Walker M.D., Ph.D. Chief Medical Adviser 1959
Mr. Simon Robertson C.A., B.Bus, M Appl. Fin, CA Company Sec. NA
Mr. Vincent P. Ippolito MD & Executive Chairman 1959

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.

Our Company

Useful Links

Contact Us

ISO Certified Market Research

Kalkine Solutions Private Limited, authorized representative of Kalkine Pty Ltd, holds ISO 27001:2022 certification bearing Certificate No.- IC-IS-2404072

Our Company

Useful Links

Contact Us

Disclaimer

The information given by Kalkine Pty Ltd ABN34 154 808 312 (Australian Financial Services License Number 425376) on this website is general information or advice only.

It does not take into account any of your personal objectives, circumstances or needs. Choosing an investment is an important decision. If you do not feel confident making a decision based on the recommendations Kalkine has made in our reports, you should consider obtaining personal advice from an authorised adviser.

There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. Terms & Conditions have been provided for our services, please go through them and also read our Financial Services Guide.

Our website may contain information on past performance of particular investments. Past performance is not an indicator of future performance. Hypothetical returns may not reflect actual performance. Any displays of potential investment opportunities are for sample purposes only and may not actually be available to investors.

The information on the website does not constitute an offer to sell securities or a solicitation of an offer to buy securities. Our reports contain general recommendations to invest in securities.

Copyright 2024 Krish Capital Pty. Ltd. All rights reserved. No part of this website, or its content, may be reproduced in any form without our prior consent.